5707 N. 22nd Street
Tampa, FL 33610
P:813.272.2244
F:813.272.3766

Make Donation

Medical Disorders
Resources
Basic InformationLookupsLatest News
Metabolomic Profiles Differ With Macular DegenerationExtended Thromboprophylaxis Safe, Effective After Liver SurgeryExercise May Stem Kidney Damage in Lupus PatientsMinorities Exposed to Dirtier Air, U.S. Study FindsDoctors Eye the Danger From 'Nerf' GunsHealth Tip: Preventing Food Allergies While Dining OutIt's a Food Allergy! Where's the School Nurse?Lower Mortality Risk Seen With Statin Use in Older MenSleep Quality, Duration Linked to CKD ProgressionSelena Gomez's Kidney Transplant Puts Lupus Center StageVision Problems Common in Babies Infected With ZikaSmoking, Poor Diet Lead Global Death CausesWhich Single Behavior Best Prevents High Blood Pressure?Traces of Tattoo May Reach the Lymph NodesVitamin D Deficiency Tied to Neuropathic Pain'Upside' to Diabetes Really Isn'tSemen Harbors Wide Range of VirusesHeath Tip: Contact Lenses Aren't Risk-FreeDiabetes Threatens Kidneys, Vision of Millions of AmericansNew Guideline Aims to Help Doctors Diagnose Head, Neck Masses'Microbiomes' May Hold Key to Kids' Ear InfectionsWarfarin, Rivaroxaban Similarly Safe, EffectiveHealth Tip: Leading Causes of Food PoisoningER Visits for These 3 Health Woes Don't Have to Happen'Modest at Best' Discriminatory Ability for CBC Test in InfantsDo E-Cigarettes Damage Blood Vessels?'Healthy' Obese Still Face Higher Heart RisksTake a Stand Against Sitting Too MuchGreater Height Tied to Higher Risk of Venous ThromboembolismZika Virus Preferentially Targets Glioblastoma Stem CellsBiomarkers Can Predict Rapid Drop in Renal Function in T2DMPeople Picking Up Infection From Pet Store Puppies' Poop: CDCHeath Tip: Getting Rid of Head LiceThe Health Risks of Long Work WeeksLupus Hits Certain Groups HarderSocioeconomic Conditions Affect Metabolic Syndrome RiskAirway Mucin Concentrations May Help Predict Chronic BronchitisCenter Surgical Volume Linked to LVAD Patient OutcomesGuinea Pigs Harbor a Hidden Health HazardHealth Tip: Antibiotic-Resistant BacteriaFor City Kids With Asthma, Nearby Green Space Is KeyThe Best Way to Diagnose a Food AllergyBudget Cuts Threaten Research on Antimicrobial ResistanceIntensive BP Control Associated With Increased CKD RiskNo Easy Road Back for Ebola SurvivorsReduced Asthma Exacerbations Seen With TezepelumabEarly Respiratory Infections Tied to Celiac in High-Risk ChildrenStatins Help Healthy People Lower Their 'Bad' CholesterolRemember This: A Healthy Body Keeps the Mind Sharp, TooAcid Reflux? Try Going Vegetarian
Links
Related Topics

Warfarin, Rivaroxaban Similarly Safe, Effective


HealthDay News
Updated: Sep 12th 2017

new article illustration

TUESDAY, Sept. 12, 2017 (HealthDay News) -- For cases of mild atrial fibrillation (AF)-related acute ischemic stroke, rivaroxaban and warfarin are similarly safe and effective at preventing recurrent stroke, according to a study published online Sept. 11 in JAMA Neurology.

Keun-Sik Hong, M.D., from Inje University in Goyang, South Korea, and colleagues compared rivaroxaban or warfarin sodium for prevention of early recurrent stroke in patients with AF-related acute ischemic stroke. Patients were randomized (1:1) to receive rivaroxaban (10 mg/day for five days followed by 15 or 20 mg/day; 95 participants) or warfarin with a target international normalized ratio of 2.0 to 3.0 (88 participants), for four weeks.

The researchers found that the two groups showed no differences in the primary composite end point (P = 0.49) or its individual components: new ischemic lesion (relative risk [RR], 0.83; 95 percent confidence interval, 0.54 to 1.26; P = 0.38) or new intracranial hemorrhage (RR, 1.10; 95 percent confidence interval, 0.70 to 1.71; P = 0.68). Each group had one clinical ischemic stroke. All new intracranial hemorrhages were asymptomatic hemorrhagic transformations. Rivaroxaban was associated with reduced hospitalization length compared with warfarin (median, 4.0 days versus 6.0 days; P < 0.001).

"In mild AF-related acute ischemic stroke, rivaroxaban and warfarin had comparable safety and efficacy," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Bayer, which partially funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)